Welcome to visit Zhongnan Medical Journal Press Series journal website!

Home Articles Vol 32,2023 No.2 Detail

Relationship between HLA-B*1502 gene polymorphism and skin adverse reactions caused by aromatic ASMs in children with epilepsy of different nationalities in Xinjiang

Published on Feb. 15, 2023Total Views: 1047 times Total Downloads: 428 times Download Mobile

Author: Ting ZHAO 1 Hong-Jian LI 1 Yan SUN 2 Ting-Ting WANG 1 Jie FENG 1 Hui-Lan ZHANG 1 Hui-Dong BAI 1 Wei-Jiang ZHU 1 Yan-Ju LI 1 Lu-Hai YU 1

Affiliation: 1. Department of Pharmacy, People’s Hospital of Xinjiang Uygur Autonomous Region(Institute of Clinical Pharmacy of Xinjiang Uygur Autonomous Region) , Urumqi 830001, China 2. Department of Neurology, Children’s Hospital of Xinjiang Uygur Autonomous Region(Xinjiang Hospital of Beijing Children’ Hospital ), Urumqi 830001, China

Keywords: Epilepsy Anti-seizure medications Skin adverse reactions HLA-B*1502 gene

DOI: 10.19960/j.issn.1005-0698.202302004

Reference: Ting ZHAO, Hong-Jian LI, Yan SUN, Ting-Ting WANG, Jie FENG,Hui-Lan ZHANG, Hui-Dong BAI, Wei-Jiang ZHU, Yan-Ju LI, Lu-Hai YU.Relationship between HLA-B*1502 gene polymorphism and skin adverse reactions caused by aromatic ASMs in children with epilepsy of different nationalities in Xinjiang[J].Yaowu Liuxingbingxue Zazhi,2023, 32(2): 151-157..DOI: 10.19960/j.issn.1005-0698.202302004.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To compare the HLA-B*1502 allele carrier rate and allele frequency in Uygur, Han and Kazak children with epilepsy, and to evaluate the risk of inducing adverse skin reactions by using aromatic ring anti-seizure medications (ASMs) in HLA-B*1502-positive children.

Methods  460 children who were treated in our hospital from January 2019 to August 2022, were detected HLA-B*1502TA and HLA-B*1502TB genotypes by fluorescent staining in situ hybridization sequencing technology before the first use of ASMs and were implemented medication guidance were retrospec-tively collected, and their genotypes and skin-type adverse drug reactions were analyzed.

Results  The mutation rates of HLA-B*1502 gene in children with Uyghur, Han and Kazakh epilepsy were 47.41%, 41.57% and 54.84%, respectively. The HLA-B*1502 heterozygous mutant gene in Kazakh chil-dren with epilepsy was significantly higher than that in Han children (P<0.05). The body mass indices of HLA-B*1502 wild-type genomes of children with Uyghur, Han and Kazakh epilepsy were significantly higher than those of children in the mutant group (P<0.05). 247 wild-type children with HLA-B*1502 did not develop skin adverse reactions after continuing to take aromatic ASMs, 12 children with HLA-B*1502 homozygous mutant adjusted to ASMs with other mechanisms of action, 56 of the 201 heterozygous mutant patients continued to use aromatic ASMs, and 5 children developed maculopap-ular rash, Stevens Johnson syndrome and toxic epidermal necrolysis within three weeks of medica-tion.

Conclusion  HLA-B*1502 gene testing is necessary for the initial clinical use of aromatic ASMs for the control and treatment of seizures in children.

Full-text
Please download the PDF version to read the full text: download
References

1.Sang T, Xiang T, Zhu SN, et al. Treatment-related costs of childhood epilepsy in mainland china: a pre-liminary study in a tertiary pediatric epilepsy center [J]. J Child Neurol, 2019, 34(2): 68-73. DOI: 10.1177/0883073818811176.

2.王宇卉. 解读"中国抗癫痫药物治疗专家共识2011"[J]. 世界临床药物, 2012, 33(1): 63-67. [Wang YH. Interpre-tation of "Chinese expert consensus on antiepileptic drug treatment 2011"[J]. World Clinical Medicinem, 2012, 33(1): 63-67.] DOI: CNKI:SUN:GWHH.0.2012-01-021.

3.Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial[J]. Lancet, 2007, 369(9566): 1000-1015. DOI: 10.1016/S0140-6736(07)60460-7.

4.Wong A, Malvestiti AA, Hafner MF. Stevens-Johnson syndrome and toxic epidermal necrolysis:a re-view[J]. Rev Assoc Med Bras, 2016, 62(5): 468-473. DOI: 10.1590/1806-9282.62.05.468.

5.高婷婷, 龙琴. Stevens-Johnson 综合征和中毒性表皮坏死松解症发病机制的研究进展[J]. 中华眼科杂志, 2016, 52(9): 708-713. [Gao TT, Long Q. Research progress on the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Chinese Journal of Ophthalmology, 2016, 52(9): 708-713.] DOI: 10.3760/cma.j.issn.0412-4081.2016.09.016

6.Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous ad-verse reactions in Asians[J]. Neurology, 2017, 88(1): 78-86. DOI: 10.1212/WNL.0000000000003453.

7.Sabourirad S, Mortezaee R, Mojarad M, et al. Investigating the association of Lamotrigine and Pheny-toin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian popu-lation[J]. Exp Dermatol, 2021, 30(2): 284-287. DOI: 10.1111/exd.14240.

8.Shafeng N, Han DF, Ma YF, et al. Association between the HLA-B*1502 gene and mild maculopapular exanthema induced by antiepileptic drugs in Northwest China[J]. BMC Neurol, 2021, 21(1): 340. DOI: 10.1186/s12883-021-02363-w.

9.童玉芬,李建新. 新疆各民族人口的空间分布格局及变动研究 [J]. 新疆大学学报, 2001, (3): 11-20. [Tong YF, Li JX. Spatial distribution pattern and changes of population of various ethnic groups in Xinjiang[J]. Journal of Xinjiang University, 2001, (3): 11-20.] DOI: 10.3969/j.issn.1001-5558.2001.03.003.

10.Yao YG, Kong QP, Zhu CL, et al. Different matrilineal contributions to genetic structure of ethnic groups in the silk road region in China[J]. Mol Biol Evol, 2004, 21(12): 2265-2280. DOI: 10.1093/molbev/msh238.

11.于鲁海,李红健,赵婷,等. 新疆癫痫患儿HLA-B基因多态性与奥卡西平所致斑丘疹的相关性研究[J]. 中国医院药学杂志, 2021, 41(1): 13-16, 41. [Yu LH, Li HJ, Zhao T, et al. Association between HLA-B gene polymor-phisms and oxcarbazepine-induced maculopapular rash in children with epilepsy in Xinjiang[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(1): 13-16, 41.] DOI: 10.13286/j.1001-5213.2021.01.03.

12.Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs[J]. N Engl J Med, 1994, 331(19): 1272-1285. DOI: 10.1056/NEJM199411103311906.

13.Zhang JZ, Lei ZX, Xu C, et al. Current perspectives on severe drug eruption [J]. Clin Rev Allergy Immunol, 2021, 61(3): 282-298. DOI: 10.1007/s12016-021-08859-0.

14.Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbam-azepine-induced severe cutaneous adverse drug reactions in a Thai population[J]. Epilepsia, 2010, 51(5): 926-930. DOI: 10.1111/j.1528-1167.2010.02533.x.

15.Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population[J]. Int J Dermatol, 2011, 50(2): 221-224. DOI: 10.1111/j.1365-4632.2010.04745.x.

16.Liao WP, Shi YW, Min FL. HLA-B*1502 screening and toxic effects of carbamazepine[J]. N Engl J Med, 2011, 365(7): 672-673. DOI: 10.1056/NEJMc1105467.

17.Shi YW, Min FL, Qin B, et al. Association between HLA and Stevens-Johnson syndrome induced by car-bamazepine in Southern Han Chinese: genetic markers besides B*1502[J]. Basic Clin Pharmacol Toxicol, 2012, 111(1): 58-64. DOI: 10.1111/j.1742-7843.2012.00868.x.

18.邵静茹, 潘英英, 邬彩红, 等. 严重药物不良反应分子标志物HLA-B*58:01、HLA-B*15:02和HLA-A*31:01在山东汉族人群中的分布[J]. 临床检验杂志, 2021, 39(9): 701-704. [Shao JR, Pan YY, Wu CH, et al. Distribution of molecular markers HLA-B*58:01, HLA-B*15:02 and HLA-A*31:01 in Han population in Shandong prov-ince[J]. Journal of Clinical Laboratory Laboratory, 2021, 39(9): 701-704.] DOI: 10.13602/j.cnki.jcls.2021.09.13.

19.黎红, 王玉芬, 杨阳, 等. 长治地区人群中HLA-B*1502基因频率分析[J]. 临床医药实践, 2021, 30(5): 363-365, 398. [Li H, Wang YF, Yang Y, et al. Frequency analysis of HLA-B*1502 gene in population in Changzhi area[J]. Clinical Medicine Practice, 2021, 30(5): 363-365, 398.] DOI: 10.16047/j.cnki.cn14-1300/r.2021.05.012.

20.孟琳懿, 王春梅, 姜志虎, 等. 140例癫痫患儿HLA-B*1502基因检测分析及用药风险评估[J]. 医药导报, 2018, 37(11): 1409-1411. [Meng LY, Wang CM, Jiang ZH, et al. HLA-B*1502 gene detection analysis and med-ication risk assessment in 140 children with epilepsy[J]. Herald of Medicine, 2018, 37(11): 1409-1411.] DOI: 10.3870/j.issn.1004-0781.2018.11.028.

Popular papers
Last 6 months